Vivos Therapeutics (VVOS) Retained Earnings (2019 - 2025)
Historic Retained Earnings for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to -$118.5 million.
- Vivos Therapeutics' Retained Earnings fell 1686.39% to -$118.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.5 million, marking a year-over-year decrease of 1686.39%. This contributed to the annual value of -$104.2 million for FY2024, which is 1196.76% down from last year.
- According to the latest figures from Q3 2025, Vivos Therapeutics' Retained Earnings is -$118.5 million, which was down 1686.39% from -$113.1 million recorded in Q2 2025.
- Vivos Therapeutics' 5-year Retained Earnings high stood at -$38.7 million for Q1 2021, and its period low was -$118.5 million during Q3 2025.
- For the 5-year period, Vivos Therapeutics' Retained Earnings averaged around -$82.0 million, with its median value being -$86.7 million (2023).
- Per our database at Business Quant, Vivos Therapeutics' Retained Earnings crashed by 5883.96% in 2022 and then crashed by 1165.74% in 2025.
- Over the past 5 years, Vivos Therapeutics' Retained Earnings (Quarter) stood at -$55.6 million in 2021, then tumbled by 42.87% to -$79.5 million in 2022, then decreased by 17.09% to -$93.1 million in 2023, then dropped by 11.97% to -$104.2 million in 2024, then fell by 13.74% to -$118.5 million in 2025.
- Its Retained Earnings was -$118.5 million in Q3 2025, compared to -$113.1 million in Q2 2025 and -$108.1 million in Q1 2025.